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Abstract
Background and objectives: High blood pressure increases the probability of insulin resistance and hyperinsuline-
mia. Also, insulin resistance can be defined as a risk factor for hypertension. The present study investigated the 
relationship between hypertension and insulin resistance in non-diabetic participants who were referred to Qazvin 
Metabolic Diseases Center. 
Material and methods: In this cross sectional study, 1103 participants (111 non-diabetic with newly diagnosed 
hypertension and 992 normotensive subjects aged ≥ 20 years) were enrolled from September 2014 to April 2016 
in Qazvin (Iran). Systolic and diastolic blood pressure, insulin resistance, waist circumference, body mass index, 
triglycerides, cholesterol, LDL-cholesterol, fasting blood glucose (FBG) were measured. Fasting triglyceride to high-
density lipoprotein cholesterol ratio (TG/HDL-C) was used as a surrogate of insulin resistance. Data were analyzed 
using SPSS software and p < 0.05 was assumed as significant level. 
Results: Ten percent of all participants had hypertension. TG/HDL-C was 3.78 ± 3.28 in non-HTN and 5.76 ± 5.35 
in HTN participants (p < 0.001). The frequency of all cardio-metabolic risk factors (except HDL cholesterol level) 
was higher in hypertensive group, after adjusting for age and gender (p < 0.001). 
Conclusion: Based on these results, essential hypertension is associated with a higher prevalence of hyperinsulinemia 
and insulin resistance in the non-diabetic community in Iran.
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Introduction
Hypertension (HTN) is one of the most important 
and constantly increasing global health problems 
[1]. Hypertension is a well-known modifiable risk 
factor for cardiovascular diseases, chronic renal fail-
ure, stroke, and a high morbidity rate [2]. Cardio-
vascular diseases affect more than 1 billion people 
worldwide. They are responsible for more than 
10 million preventable deaths globally each year 
[3]. A linear association is between cardiovascular 
and cerebrovascular events with a wide spectrum 
of blood pressure elevation in clinical presentation 
severity. In subjects aged between 40 and 70 years, 
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each 20-mm Hg increase in systolic or 10-mm Hg 
in diastolic blood pressures doubles risk of cardio-
vascular and cerebrovascular events [4, 5]. Around 
the world, it is estimated that the prevalence of 
hypertension will increase up to > 1.5 billion in the 
year 2025 [6]. Hypertension is present in more than 
50% of patients with diabetes mellitus (DM) and 
contributes significantly to both micro and macro-
vascular disease in diabetic patients [7]. Similar to 
the prevalence of type 2 diabetes in the Middle East, 
HTN is rising and it is estimated to be an important 
public health problem in this region [8]. The com-
mon findings in hypertension are hyperinsulinemia 
and insulin resistance [9, 10]. It has been estimated 
that about half of patients with essential hyperten-
sion are insulin-resistant [11]. Insulin resistance is 
defined as a decrease in the physiological response to 
insulin and compensatory over-secretion of insulin. 
In this situation, the transport of glucose into the 
skeletal muscle and fat cells are impaired. Therefore, 
pure results are hyperinsulinemia and hyperglyce-
mia [12]. Hyperinsulinemia may directly promote 
atherosclerosis by enhancing LDL-cholesterol ac-
cumulation in vessel walls, vascular smooth muscle 
migration, proliferation, augmenting connective 
tissue synthesis in the arterial wall, and decreas-
ing the regression of lipid plaques [13]. There are 
several reports that there is a link between essential 
hypertension and insulin resistance; however, the 
underlying pathogenesis seems inherently contradic-
tory [14]. It is important that more studies proposed 
for assaying the association between blood pressure 
elevation and other underlying pathologies [15, 16]. 
In the Middle East countries due to demographic 
transition and lifestyle westernization, the incidence 
of obesity and associated complications are increased 
[3, 17]. Similar to other countries in the world, 
the prevalence of hypertension and metabolic syn-
drome is growing in Iran, so that the prevalence of 
hypertension has been reported by about 20% and 
23% in men and women, respectively (2004–2006). 
Total prevalence is about 32.5% [18, 19]. The cur-
rent study was designed to evaluate the association 
between essential hypertension and insulin resis-
tance among non-diabetic adult participants that 
are newly diagnosed as hypertensive in the Qazvin 
province of Iran.
Material and methods
Data sets and subjects
This cross-sectional study included 1103 volunteers 
(111 non-diabetic patients with newly diagnosed 
hypertension and 992 normotensive individuals aged 
20 years or older) who were referred to the Qazvin 
Metabolic Diseases Center (Iran) from September 
2014 to April 2016.
All participants (526 men and 577 women) signed 
written informed consent before enrollment. Their 
responses were confidential. The ethics board of the 
Qazvin University of Medical Science approved the 
study. Participants were selected by a multistage clus-
ter random sampling method. The inclusion crite-
ria were newly diagnosed hypertension and normal 
population aged 20 years or older in the Qazvin. 
Exclusion criteria were: smoking, malignant or ac-
celerated hypertension, heart failure, cardiomyopa-
thy, peripheral vascular disease, past medical history 
of cardiovascular or cerebrovascular disease, or any 
secondary hypertension (liver and kidney diseases, 
hyperthyroidism, or aldosteronism, etc.). 
Data collection
The demographic data, such as age, gender, prior 
history of treatment for diabetes, and hypertension 
were collected with interview sessions. The anthro-
pometric characteristics (weight, height, waist cir-
cumference, and hip) were measured by standard 
methods. Bodyweight was measured to the nearest 
0.1 kg with a balanced-beam scale while wearing 
light clothing, and height was measured with a sta-
diometer to the nearest 0.5 cm. Body mass index 
(BMI) was calculated based on the weight/(height)² 
formula. Participants with a BMI between 25 and 
29.9 kg/m2 were considered overweight. Obesity 
was defined as BMI of more than 30 kg/m2.Waist 
circumference between the lowest rib and the iliac 
crest, at the level of the umbilicus, was measured 
in duplicate to the nearest millimeter using flexible 
tape. Waist circumference (WC) equal or more than 
85cm in females and equal or more than 90 cm in 
males was considered central obesity. Blood pressure 
was measured by a calibrated sphygmomanometer. 
Systolic (Korotkoff phase I) and diastolic (Korotkoff 
phase V) blood pressure was measured twice a day 
on the left upper arm and the average of the two 
amounts was considered [20]. 
Biochemical measurement
Venous blood samples were collected from all par-
ticipants after 12 hours of overnight fast. Blood 
samples were stored at 70ºC. The serum was sepa-
rated by centrifugation at 3000 rpm for 15 min. 
Total cholesterol (TC), low-density lipoprotein cho-
lesterol (LDL-C), triglycerides (TG), glucose, and 
high-density lipoprotein (HDL-C) were measured 
by the calibrated automatic biochemical analyzer 
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(HITECH 7080, Tokyo, Japan). Enzymatic meth-
ods were applied to estimate levels of TC, LDL, 
glucose, and TG. Insulin levels were measured with 
a sensitivity of 0.25 (μU/mL) via an electrochemilu-
minescence immunoassay (ECLIA). The ratio of tri-
glyceride (TG) to high-density lipoprotein (HDL-C) 
(TG/HDL-C) was used as a measure of insulin re-
sistance. According to several studies’ definitions, 
insulin-resistant (IR) was TG/HDL-C ratio greater 
than 3.0, and insulin-sensitive (IS) was TG/HDL-C 
ratio less than 2.0 [10, 21]. LDL-C was calculated 
using Friedwald’s formula (TG ≤ 400 mg/dL). Di-
agnosis of the cardiometabolic risk factors in adults 
including women and men is based on revised Na-
tional Cholesterol Education Program-Adult Treat-
ment Panel III (NCEP/ATPIII) and World Health 
Organization (WHO) criteria. Metabolic syndrome 
was defined by the presence of three or more follow-
ing findings: (1) abdominal obesity (WC ≥ 90 cm in 
men and ≥ 85 cm in women) or BMI > 30, (2) a high 
triglyceride level ≥ 150 mg/dL or medical therapy 
for hypertriglyceridemia; (3) a low HDL choles-
terol level (< 40 mg/dL for men and < 50mg/dL 
for women); (4) high blood pressure (systolic ≥ 130 
mm Hg and diastolic ≥ 85 mm Hg or antihyperten-
sive medical therapy; and (5) a high fasting plasma 
glucose concentration ≥ 100 mg/dL or medical 
treatment for type 2 DM [21]. 
Statistical analysis
Chi-square and odds-ratio tests were used to com-
pare qualitative parameters. To compare quantita-
tive variables, we used unpaired student t test or 
Mann-Whitney test, as appropriate. For a compara-
tive analysis of quantitative variables between HTN 
or insulin resistance subgroups, one-way ANOVA 
was used. To control confounding variables such as 
age and gender, a partial correlation by Spearman r 
was applied to find a significant correlation between 
clinical and biochemical characteristics. IBM SPSS 
Statistics 22.0 for Windows (IBM Corp., Armonk, 
NY, USA) was used for all the statistical analyses, 
and P< 0.05 was assumed as significant differences.
Results
Demographical characteristic of participants
Of the total of 1103 participants, 47.7% were male 
and 52. 3% were female. There were 10% partici-
pants with hypertension. The mean age of the sub-
jects was 40.08 ± 10.33 years (Tab. 1).
Comparative biochemical characteristics of 
participants based on gender
Comparing the two sexes except for the mean cho-
lesterol, LDL, and systolic and diastolic pressure, all 
of the variables had significant differences (p < 0.00) 
(Tab. 2).
Table 1. Age distribution of the study population
Age (yrs) Male Female Total 
20–29 78 118 17.8%
30–39 83 184 24.3%
40–49 261 218 43.6%
50–59 82 38 10.9%
60–70 23 14 7.9%
Table 2. Comparison (mean ± SD) of the clinical and biochemical characteristics of participants based on gender
Variables Male  (n = 527)
Female  
(n = 572) F p value
WC [cm] 92.0 ± 0.40302 87.2669 ± 0.46560 20.086 0.000
BMI [kg/m2] 25.1502 ± 0.16170 26.6907 ± 0.20338 30.332 0.000
TG [mg/dL] 166.4722 ± 5.26090 128.7887 ± 2.92453 26.683 0.000
TC [mg/dL] 184.3808 ± 1.67147 182.2814 ± 1.71750 0.034 0.381
HDL [mg/dL] 38.4333 ± 0.37941 45.3373 ± 0.46345 18.871 0.000
LDL [mg/dL] 109.3038 ± 1.07617 104.9747 ± 1.11455 0.744 0.389
FBG [mg/dL] 99.6729 ± 1.19488 99.8213 ± 1.33409 5.286 0.000
Insulin [mU/mL] 11.8186 ± 0.35082 12.2111 ± 0.29846 0.120 0.002
SBP [mg Hg] 115.4411 ± 0.74522 109.5407 ± 0.74548 0.064 0.800
DBP [mg Hg] 73.7500 ± 0.50089 69.6267 ± 0.49482 0.559 0.455
WC — waist circumference; BMI — body mass index; TG — triglycerides; TC — total cholesterol; HDL — high density lipoprotein; LDL — low density lipoprotein; FBG — fasting blood glucose; SBP — systolic blood 
pressure; DBP — diastolic blood pressure
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Clinical and biochemical characteristics 
in non-HTN and HTN individuals
In males, there were significant differences between 
patients with hypertension (HTN) and non-hy-
pertensive participants in WC, BMI, lipid profiles 
(including: TG, TC, HDL-C, and LDL-C), fasting 
blood glucose (FBG), insulin level, systolic, and dia-
stolic blood pressure (p < 0.00) (Tab. 3).
In women participants, there were significant dif-
ferences between HTN non-HTN participants in all 
mentioned variables, except for total cholesterol and 
LDL-C (p < 0.00) (Tab. 4).
Clinical and biochemical characteristics  
in insulin-resistant and insulin-sensitive  
individuals
There were significant differences in insulin resis-
tance and biochemical variables such as WC, BMI, 
lipid profiles, FBG (except in males), and insulin 
level, in both male and female groups, between in-
sulin resistant and insulin-sensitive participants 
(p < 0.000). 
Also, in both genders, the systolic (M: 116.82 ± 
1 vs. 112. 72 ± 1.07 mm Hg, F; 113.67 ± 1.29 vs. 
107.18 ± 0.91 mm Hg) and diastolic (M: 74.49 ± 
0.57 vs. 72. 19 ± 0.72 mm Hg, F; 72. 51 ± 0.86 vs. 
68.1 ± 0.6 mm Hg) blood pressure were significantly 
higher in insulin-resistant patient than in insulin-
sensitive participants (p < 0.00) (Tab. 5, 6).
Cardio-metabolic factors in HTN  
vs. non-HTN participants
The mean of TG/HDL as an index of insulin resis-
tance or sensitivity was 3.97 ± 3.59 among all of the 
participants. This index was different between HTN 
and non-HTN participants. TG/HDL-C was 3.78 ± 
3.28 in non-HTN and 5.76 ± 5.35 in HTN partici-
pants (p < 0.001). Overall, the correlation between 
HTN and cardio-metabolic factors in both genders 
was considerable; the frequency of all cardiometabol-
ic risk factors (except HDL and TC level) was higher 
after adjusting for age and gender in the hypertensive 
group (Tab. 5, 6). 
Discussion
The prevalence of high blood pressure is increasing 
rapidly across the world, especially in developing 
countries like Iran. This epidemiological transmis-
sion in developing countries leads to an alarming in-
crease in non-transmitted diseases, especially diabetes 
Table 3. Comparison (mean ± SD) of the clinical and biochemical characteristics in male patients with hypertension (HTN) and without 
hypertension (non-HTN) 
Variables Non-HTN  (n = 371)
HTN  
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Table 4. Comparison (mean ± SD) of the clinical and biochemical characteristics in female patients with hypertension (HTN) 
and without hypertension (non-HTN)
Variables Non-HTN (n = 474)
HTN  
(n = 102) F p value
WC [cm] 86.1540 ± 0.50098 92.4455 ± 1.09729 0.131 0.000
BMI [kg/m2] 26.1891 ± .22249 29.0764 ± 0.43878 0.398 0.000
TG [mg/dL] 123.1947 ± 3.11338 155.2434 ± 7.54399 3.147 0.000
TC [mg/dL] 181.5674 ± 1.81223 185.5929 ± 4.32648 0.750    0.325
HDL [mg/dL] 45.8158 ± 0.50983 43.0636 ± 1.10976 0.539   0.026
LDL [mg/dL] 104.2556 ± 1.21746 108.5172 ± 2.78362 0.321 0.163
FBG [mg/dL] 98.2074 ± 1.38064 107.5455 ± 3.91051 8.005   0.026
Insulin [mU/mL] 11.7356 ± 0.32458 14.5660 ± 0.71456 0.086 0.000
SBP [mg Hg] 103.6498 ± 0.54905 137.1569 ± 1.47046 2.263 0.000
DBP [mg Hg] 65.9599 ± 0.37506 86.6667 ± 1.14756 10.517 0.000
WC — waist circumference; BMI — body mass index; TG — triglycerides; TC — total cholesterol; HDL — high density lipoprotein; LDL — low density lipoprotein; FBG — fasting blood glucose; SBP — systolic blood 
pressure; DBP — diastolic blood pressure
Table 5. Comparison (mean ± SD) of the clinical and biochemical characteristics in insulin-resistant and insulin-sensitive male individuals
Variables TG/HDL £ 3
(n = 199)
TG/HDL > 3
(n = 321) F p value
WC [cm] 89.2778 ± 0.67473 93.6688 ± 0.48313 2.956 0.000
BMI [kg/m2] 23.9278 ± 0.27410 25.8763 ± 0.18906 6.456 0.000
TG [mg/dL] 90.9196 ± 1.57376 208.9938 ± 6.05391 106.618 0.000
TC [mg/dL] 171.3769 ± 2.30311 191.4966 ± 2.08855 3.041 0.000
HDL [mg/dL] 44.6157 ± 0.56950 34.6006 ± 0.36586 9.608 0.000
LDL [mg/dL] 103.1734 ± 1.65782 113.3184 ± 1.35321 0.000 0.000
FBG [mg/dL] 97.3714 ± 1.22056 100.9121 ± 1.77307 3.712 0.149
Insulin [mU/mL] 10.5172 ± 0.41689 12.6000 ± 0.50266 1.868 0.004
SBP [mg Hg] 112.7259 ± 1.07529 116.8281 ± 1.00013 3.934 0.005
DBP [mg Hg] 72.1939 ± 0.72891 74.4984 ± 0.67097 9.250 0.026
WC — waist circumference; BMI — body mass index; TG — triglycerides; TC — total cholesterol; HDL — high density lipoprotein; LDL — low density lipoprotein; FBG — fasting blood glucose; SBP — systolic blood 
pressure; DBP — diastolic blood pressure
Table 6. Comparison (mean ± SD) of the clinical and biochemical characteristics in insulin-resistant and insulin-sensitive female 
individuals
Variables TG/HDL ≤ 3(n = 346)
TG/HDL > 3 
(n = 211) F p value
WC [cm] 84.6908 ± 0.59562 91.5308 ± 0.68886 4.350 0.000
BMI [kg/m2] 25.8013 ± 0.27636 28.0422 ± 0.27304 14.230 0.000
TG [mg/dL] 89.2075 ± 1.33481 193.8820 ± 4.76650 154.072 0.000
TC [mg/dL] 172.8957 ± 1.79029 197.7166 ± 3.01460 7.352 0.000
HDL [mg/dL] 49.9438 ± 0.52805 37.7616 ± 0.55819 7.823 0.000
LDL [mg/dL] 98.4184 ± 1.22199 115.7569 ± 1.94344 7.135 0.000
FBG [mg/dL] 94.8075 ± 1.06864 108.0668 ± 2.97811 41.222 0.000
Insulin [mU/mL] 11.3238 ± 0.38298 13.6519 ± 0.45993 0.585 0.000
SBP [mg Hg] 107.1821 ± 0.91860 113.6730 ± 1.29037 2.319 0.000
DBP [mg Hg] 68.1014 ± 0.60911 72.5118 ± 0.86324 3.906 0.000
WC — waist circumference; BMI — body mass index; TG — triglycerides; TC — total cholesterol; HDL — high density lipoprotein; LDL — low density lipoprotein; FBG — fasting blood glucose; SBP — systolic blood 
pressure; DBP — diastolic blood pressure
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and high blood pressure [23]. The prevalence of both 
systolic and diastolic hypertension in our communi-
ty-based study was about 10% of the total popula-
tion, with no significant difference between men and 
women. Various studies have been carried out on the 
prevalence of HTN in different parts of Iran, which 
reported different rates [24]. A new systematic and 
meta-analytical review (based on studies published 
in national and international journals between 2004 
and 2018) stated that the overall prevalence of HTN 
in Iranian society was 25% and the prevalence of 
HTN in older adults was 42% higher than other age 
groups [25]. The outcome of another cross-sectional 
study, which was conducted among 2,107 Iranian 
adult residents of Isfahan, has shown that the overall 
prevalence of HTN was 17.3% (18.9 and 15.5% in 
men and women) [26]. The highest prevalence of 
HTN was found to be 46.0% among adults in Afri-
ca, in contrast to 35.0% among American adults [27] 
and roughly 23.0% among Canadian adults [28]. In 
this study, the prevalence of HTN was lower than 
in similar studies [25–28]. The reason might be that 
normal population participated in our study, accord-
ing to their reference to the center, because of the 
prevalence of HTN can be affected by demographic 
factors, such as age, race, gender and socioeconomic 
status, and type of study (cross-sectional or cohort 
study) [29]. In this study, the relationship between 
hypertension and insulin resistance was examined. 
The results showed that the mean of TG/HDL as 
an index of insulin-resistant was significantly dif-
ferent between untreated essential hypertensive and 
normotensive participants. This finding is consistent 
with most studies, which referred to the concur-
rence of hypertension and insulin resistance [9, 10]. 
These two variables are the components of metabolic 
syndrome and often coexist [30]. It’s estimated that 
about 50% of patients with essential hypertension 
have been suffering from insulin-resistant or hyperin-
sulinemia, and glucose intolerance. Also, up to 80% 
of patients with type 2 diabetes were hypertensive 
[11, 30]. Clinical studies have shown a strong as-
sociation between essential hypertension and insulin 
resistance/compensatory hyperinsulinemia. It should 
be noted the causal nature of them were not com-
pletely explained [16]. Some researchers suggest that 
insulin resistance and hyperinsulinemia are related 
to hypertension [22], while others do not support 
this theory [15]. High blood pressure and insulin 
resistance have important roles in the increase in 
cardiovascular diseases, cardiovascular (CVD) mor-
bidity, and mortality rates [31]. Accordingly, the 
reduced risk of cardiovascular diseases is dependent 
on early detection and treatment of high blood pres-
sure, correction of blood glucose level, and associated 
metabolism [32]. 
In this study, the WC, BMI, FBG, lipid profile, and 
fasting serum insulin levels were significantly higher 
in individuals with high blood pressure than in both 
normotensive and insulin-sensitive populations. This 
finding has been confirmed by similar studies [32]. 
Also, Garcia and its co-workers found abnormal glu-
cose metabolism in hypertensive cases [29]. These 
risk factors induce and aggravate HTN and insulin 
resistance. In this regard, many studies have found 
the prevalence of metabolic syndrome to be higher 
in individuals with HTN than in the general popula-
tion [33]. Additionally, the prevalence of HTN was 
higher in the insulin resistance patients. One of the 
reasons for this finding is that changes take place in the 
vascular walls associated with higher levels of plasma 
lipids that can accelerate arteriosclerosis and hyper-
tension [13, 34]. So, insulin resistance has been pro-
posed as the main underlying cause of cardiometabolic 
syndrome [9, 10]. Kim and et al. showed that four 
major risk factors for cardiovascular disease in non-
diabetic Korean elderly individuals were glucose tol-
erance impairment, dyslipidemia, hypertension, and 
obesity [35]. Insulin resistance is also associated with 
high blood pressure in obese subjects. There are still 
some questions that remain unanswered whether high 
blood pressure alone was due to insulin resistance or 
not. Interestingly, sodium is a link between hyperten-
sion and insulin resistance. Some studies suggest that 
a high-salt diet impairs insulin sensitivity in hyperten-
sive patients [36]. Insulin hypersecretion increases the 
reabsorption of sodium by activating the sympathetic 
system and alters blood pressure [37]. Of course, 
other mechanisms may include chronic inflamma-
tion and oxidative stress [32]. There are some degrees 
of chronic inflammation in obese people [37]. Also, 
excess nutrient intake can induce oxidative stress in 
the adipose tissue which is manifested by more secre-
tion of inflammatory cytokine [38]. Furthermore, 
the coexistence of insulin resistance and hypertension 
prompt premature atherosclerosis [39]. It should be 
noted that all participants with high blood pressure 
and insulin resistance had a significantly higher waist 
and wrist diameters than normal individuals. It has 
been proven that normal blood pressure is controlled 
by substances that regulate vascular tone. Therefore, 
overweight, which often is associated with hyperinsu-
linemia, stimulates endothelin 1 (ET-1) production. 
It eventually causes an arterial disturbance. In normal 
physiological conditions, NO inhibits the ET-1 ac-
tivity. Thus, the loss of endothelial-derived NO may 
increase the production of ET-1, which is important 
in the pathophysiology of hypertension [40]. 
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Conclusions 
The results of this study emphasize the positive cor-
relation between hypertension and insulin resistance. 
Despite the latest progress in preventing non-com-
municable diseases, the prevalence of HTN in the 
world, especially in developing countries, is expand-
ing.
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